{"nctId":"NCT01492361","briefTitle":"A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin","startDateStruct":{"date":"2011-11","type":"ACTUAL"},"conditions":["Cardiovascular Diseases"],"count":8179,"armGroups":[{"label":"AMR101","type":"EXPERIMENTAL","interventionNames":["Drug: AMR101","Drug: Statin therapy"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Statin therapy"]}],"interventions":[{"name":"AMR101","otherNames":["VASCEPAÂ® (icosapent ethyl)"]},{"name":"Placebo","otherNames":["matching placebo"]},{"name":"Statin therapy","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men and non-pregnant or sterile women ages 45 and older\n* Hypertriglyceridemia\n* On statin therapy for at least four weeks\n* Either having established cardiovascular disease or at high risk for cardiovascular disease\n\nExclusion Criteria:\n\n* Severe heart failure\n* Any life-threatening disease other than cardiovascular disease\n* Active severe liver disease\n* Hemoglobin A1c \\>10.0%\n* Poorly controlled hypertension\n* Planned coronary intervention (such as stent placement or heart bypass) or any non-cardiac major surgical procedure\n* Known familial lipoprotein lipase deficiency (Fredrickson Type I), apolipoprotein C-II deficiency, or familial dysbetalipoproteinemia (Fredrickson Type III)\n* Known hypersensitivity to the study product, fish and/or shellfish, or placebo\n* History of acute or chronic pancreatitis\n* Patients are excluded if using the following medications:\n\n  * PCSK9 inhibitors\n  * niacin \\>200 mg/day or fibrates;\n  * any omega-3 fatty acid medications ;\n  * dietary supplements containing omega-3 fatty acids (e.g., flaxseed oil, fish oil, krill oil, or algal oil);\n  * bile acid sequestrants","healthyVolunteers":false,"sex":"ALL","minimumAge":"45 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Composite of CV Death, Nonfatal MI (Including Silent MI), Nonfatal Stroke, Coronary Revascularization, or Unstable Angina Determined to be Caused by Myocardial Ischemia by Invasive / Non-invasive Testing and Requiring Emergent Hospitalization.","description":"The primary outcome measure was the number of patients with a first occurrence of any component of the composite of CV death, nonfatal MI (including silent MI), nonfatal stroke, coronary revascularization, or unstable angina determined to be caused by myocardial ischemia by invasive / non-invasive testing and requiring emergent hospitalization during the follow-up period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"705","spread":null},{"groupId":"OG001","value":"901","spread":null}]}]}]},{"type":"SECONDARY","title":"Composite of CV Death, Nonfatal MI (Including Silent MI), or Nonfatal Stroke.","description":"The key secondary outcome measure was the number of patients with a first occurrence of any component of the composite of CV death, nonfatal MI (including silent MI), or nonfatal stroke during the follow-up period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"459","spread":null},{"groupId":"OG001","value":"606","spread":null}]}]}]},{"type":"SECONDARY","title":"Composite of CV Death or Nonfatal MI (Including Silent MI).","description":"Number of patients with a first occurrence of any component of the composite of CV death or nonfatal MI (including silent MI) during the follow-up period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"392","spread":null},{"groupId":"OG001","value":"507","spread":null}]}]}]},{"type":"SECONDARY","title":"Fatal or Nonfatal MI (Including Silent MI).","description":"Number of patients with a first occurrence of fatal or nonfatal MI (including silent MI) during the follow-up period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"250","spread":null},{"groupId":"OG001","value":"355","spread":null}]}]}]},{"type":"SECONDARY","title":"Non-elective Coronary Revascularization Represented as the Composite of Emergent or Urgent Classifications.","description":"Number of patients with a first occurrence of non-elective coronary revascularization represented as the composite of emergent or urgent classifications during the follow-up period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"216","spread":null},{"groupId":"OG001","value":"321","spread":null}]}]}]},{"type":"SECONDARY","title":"CV Death.","description":"Number of patients with an occurrence of CV death during the follow-up period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"174","spread":null},{"groupId":"OG001","value":"213","spread":null}]}]}]},{"type":"SECONDARY","title":"Unstable Angina Determined to be Caused by Myocardial Ischemia by Invasive / Non-invasive Testing and Requiring Emergent Hospitalization.","description":"Number of patients with a first occurrence of unstable angina determined to be caused by myocardial ischemia by invasive / non-invasive testing and requiring emergent hospitalization during the follow-up period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"108","spread":null},{"groupId":"OG001","value":"157","spread":null}]}]}]},{"type":"SECONDARY","title":"Fatal or Nonfatal Stroke.","description":"Number of patients with a first occurrence of fatal or nonfatal stroke during the follow-up period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"134","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Mortality, Nonfatal MI (Including Silent MI), or Nonfatal Stroke.","description":"Number of patients with a first occurrence of any component of the composite of total mortality, nonfatal MI (including silent MI), or nonfatal stroke during the follow-up period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"549","spread":null},{"groupId":"OG001","value":"690","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Mortality.","description":"Number of patients with an occurrence of death from any cause during the follow-up period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"274","spread":null},{"groupId":"OG001","value":"310","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1252,"n":4089},"commonTop":["Diarrhoea","Hypertension","Upper respiratory tract infection","Back pain","Arthralgia"]}}}